pamiparib   Click here for help

GtoPdb Ligand ID: 12345

Synonyms: BGB-290 | BGB290 | compound 139 [PMID: 33264017] | Partruvix®
Approved drug PDB Ligand
pamiparib is an approved drug (China (2021))
Compound class: Synthetic organic
Comment: Pamiparib (BGB-290) is an orally bioavailable, selective poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2) inhibitor [2]. It was developed for antineoplastic potential. PARP inhibition is used to treat tumours with defects in their DNA repair/DNA-damage response (DDR) pathway, such as BRCA 1/2 (BReast CAncer gene 1 and 2) mutations. Pamiparib can cross the blood-brain barrier, offering potential as a treatment for brain tumours [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 0
Topological polar surface area 64.78
Molecular weight 298.12
XLogP 2.05
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1cc2[nH]c3c4c2c(c1)c(=O)[nH]nc4CN1[C@]3(C)CCC1
Isomeric SMILES C[C@]12CCCN1Cc1n[nH]c(=O)c3c4c1c2[nH]c4cc(c3)F
InChI InChI=1S/C16H15FN4O/c1-16-3-2-4-21(16)7-11-13-12-9(15(22)20-19-11)5-8(17)6-10(12)18-14(13)16/h5-6,18H,2-4,7H2,1H3,(H,20,22)/t16-/m1/s1
InChI Key DENYZIUJOTUUNY-MRXNPFEDSA-N
No information available.
Summary of Clinical Use Click here for help
Pamiparib was issued its first approval for clinical use in China (April 2021) [1]. It was indicated for the treatment of recurrent/advanced ovarian, fallopian tube or primary peritoneal cancers with germline BRCA mutations.